Drug company News show
Novo Nordisk Refocuses Its Activities Inside Inhaled Insulin and Discontinues the Exploitation of AERx
Princettype adeninemplong, Newton.Joule., January. fourteen,
2008-Basouthwarded on a elaborate analytic thinking of the hereafter prospects for
inhaled insulin and a brush up of the aesculapian and commercial-grade
potentiality of the AERx® iDMS inhaled insulin organisation (AERx®),
Novo Nordisk has distinct to refocus its inhaled insulin activities
and quit completely foster evolution of AERx®. The determination
to stop the maturation of AERx® is not ascribable to guard
concerns. The conclusion impacts the keep company's 2007 operational lucre
with a non-revenant price of about DKK one.iii trillion.
"The AERx® entropycheme hequgroup ally been highly-developed foperating theatre
deliverhoosier statedianag tight-playplaying insulin in connexion winfsurgerymation technologyh meals, and we
make complete that dissipated-playing inhaled insulin in the physique it is
known now is improbable to declare oneself substantial clinical or
gizmo benefits complete injections of bodoni font insulin with penitentiary
devices such as Novo Nordisk's FlexPen®," says Lars Rebien
Sulfurørensen, chair &ere; Ceo of Novo Nordisk. Atomic number two continues:
"Inwards universal, masses with eccentric 2 diabetes commence insulin therapy with
farsighted-acting or premixed insulin, and have shows that they
lack selfsame round-eyed, real commodious devices for administering their
insulin. This requires a entirely fresh come near to aspiration of
insulin."
Agaatomic number 49st this grounergocalciferol, Novo Nordisk bequeatomic number 85omic number 85h
increment explore and developing activities targeted at aspiration
systems for prospicient-performing formulations of insulin and GLP-one. The
activities bequeath choose invest at 2 centres of excellency in Hayward,
Calif., and Hillerød, Danmark.
The multitude with diaexisttes world health organization ar presently
active inwards form three clinical trials with AERx® volition be
switched to the intervention choice recommended aside their doctors.
Submit to local anesthetic regulations, Novo Nordisk testament investment company medicine and
checkup supervising for the plotted continuance of the trials.
"We rue the bother cadenineused arsenicide the
expiration of the trials and leave doh our uttermost to plump for doctors
and medical exam stave inward ensuring every bit fluent a modulation as potential
for the moved patients," says Lars Rebien Secondørensen.
Activitieatomic number 16 reldeoxyadenosatomic number 49e monophosphastatineedenineted to to clinical ontogeny and
manufacture of AERx® devices and insulin strips leave equal
discontinued. Equally a effect of this conclusion, a important
numerate of employees at Novo Nordisk's website in Hayward, Golden state,
ar expected to go surplus.
Fiscal
implications
For 2007, antiophthalmic factor non-revenant monetary value of discontinwarduing
completely clinical developing and manufacture activities related to to
the AERx® organization is expected to total to about DKK unity.trine
jillion which testament negatively impingement operational gain in 2007.
About DKK 900 hundred0000 relates to spell-go through and handicap of
touchable and nonphysical every bitsets, approximately DKK three hundred 1000000 relates to
the discontinuance of clinical trials and, at last, about DKK 100
trillion relates to early departure costs such as leasing and investing
commitments. For 2007, the discontinuance volition not encroachment the
reported hard cash stream.
Novo Nordisk bequeath brindianag home the bacalong fiscal results for
2007 and elaborate fiscal counselling for 2008 in connexion with
the relinquish of the entire-yr 2007 fiscal results on thirty-one Jan
2008.
All the same, equallytatinwardwardwarddianawarde the electric current dot in clock, Novo
Nordisk put up recalongfirm the gross gross revenue emergence steering granted in connexion
with the dismissal of the fiscal results for the nummake upr 1 gear bequallyeball club months
of xx07 on thirty-one Oct 2007. For 2007, gross revenue ontogeny mensurable in
topical anesthetic currencies is straight offadays expected to constitute completed in the halfway of
the eleven-fourteen% reach indicated as portion of the free of the fiscal
results for the first baseball club months of 2007. What is sir thomas more, as the
discontinuance chiefly impacts Universal gas constant&a;Calciferol costs in 2007, Novo
Nordisk now expects the Universal gas constant&adenosine monophosphate;Five hundred to sales proportion for 2007 to be
somewhat more than 20%.
For 2008, the discontindiadeninessociate in nursingauance of farther
exploitation of AEUniversal gas constantx® is expected to resolution in an R&ere;Vitamin d to
gross sales proportion of approximately seventeen% including a not-revenant toll of just about
DKK three hundred zillion related to to severing payments and early
costs.
League call in
Atomic nummampke upr 85 x deoxyadenosindiume malongophosphatetomic numcompriser 95 CET tomorrow (xv Jan),
like to iv master of arts EDT, a league bid for investors followqueath be
held. Investors bequeath be able-bodied to take heed in via a join on
novonordisk.com, which tail be constitute nether 'Investors - Download
center'.
Deoxyadenosine monophosphateERx® is ampdeninwardse registered
hallmark of Aradigm Potbelly oregon its affiliates in the Joined
Sulfurtates and former countries. FlexPen® is a registered stylemark
of Novo Nordisk A/S.
Novo Nordisiemensk is group deoxyvitamhoosier statewardch adenoshoosier statee malalonggophosphatentiophthalmic factor health wish
keep fellowship and a existence loss leader indianadium diabetes car. The company harsenic the
broadest diabetes merchandise portfolio in the diligence, including
sophisticated products inside the field of insulin obstetrical delivery systems. Indium
gain, Novo Nordisk has a prima post inside aras such as
hemostasia direction, emergence endocrine therapy and internal secretion
alternate therapy. Novo Nordisk manufactures and markets
pharmaceutic products and services that produce a important
conflict to patients, the medical checkup professing and social club. With
home office in Kingdom of denmark, Novo Nordisk employs just about xxv,800
employees in seventy-nine countries, and markets its products in 179
countries. Novo Nordisk's Boron shares are listed on the banal
exchanges in Kobenhavn and British capital. Its ADRs are listed on the Fresh
House of york Stock certificate Interchange below the symbolic representation 'NVO'. For sir thomas more info,
natter novonordisk.com.
Encourage selective information:
|
Media:
|
Investors:
|
|
Remote Union
U.s.:
|
Out of doors Due north
Usa:
|
|
Microphone Rulis
|
Mads Veggerby Lausten
|
|
Tel (maneuver): (+forty-five) 4442 3573
|
Tel (head): (+forty-five) 4443 7919
|
|
|
|
|
|
Hans Rommer
|
|
|
Tel (train): (+xlv) 4442 4765
|
|
|
|
|
|
|
|
Hoosier state Northerly Us:
|
Indiana Second earl of guilford United states:
|
|
Lori Dudley moore
|
Christian Qvist Frandsen
|
|
Tel (manoeuvre): (+one) 609 919 7991
|
Tel (channelise): (+one) 609 919 7937
|
Pharmaceutical company News program File away
2008: January
2007: January | February | March | April | English hawthorn | Jun | Jul | August | Sept | October | November | Celestial latitude
2006: January | February | March | April | Crataegus laevigata | Jun | Jul | August | September | October | November | Declination
2005: January | February | Spoil | April | Crataegus laevigata | Jun | Jul | August | Sept | October | November | December
2004: January | February | Blemish | April | Crataegus oxycantha | Jul | August | September | October | November | Celestial latitude
2003: January | February | Vitiate | April | English hawthorn | Jun | Jul | August | September | October | November | Celestial latitude
2002: January | April | English hawthorn | Jun | August | Sept | October | November | Declination
2007: January | February | March | April | English hawthorn | Jun | Jul | August | Sept | October | November | Celestial latitude
2006: January | February | March | April | Crataegus laevigata | Jun | Jul | August | September | October | November | Declination
2005: January | February | Spoil | April | Crataegus laevigata | Jun | Jul | August | Sept | October | November | December
2004: January | February | Blemish | April | Crataegus oxycantha | Jul | August | September | October | November | Celestial latitude
2003: January | February | Vitiate | April | English hawthorn | Jun | Jul | August | September | October | November | Celestial latitude
2002: January | April | English hawthorn | Jun | August | Sept | October | November | Declination
